$2.17
-0.11 (-4.82%)
Open$2.26
Previous Close$2.28
Day High$2.27
Day Low$2.17
52W High$4.53
52W Low$2.18
Volume—
Avg Volume261.5K
Market Cap75.87M
P/E Ratio0.68
EPS$2.91
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+495.9% upside
Current
$2.17
$2.17
Target
$12.93
$12.93
$7.67
$12.93 avg
$16.62
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 75.45M | 80.11M | 15.02M |
| Net Income | 8.13M | 7.77M | -500,427 |
| Profit Margin | 10.8% | 10.2% | -3.3% |
| EBITDA | -46,319,443 | -46,722,733 | -867,054 |
| Free Cash Flow | — | — | -309,659 |
| Rev Growth | -5.8% | -5.8% | +23.3% |
| Debt/Equity | 1.19 | 1.19 | 0.77 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $263.29 | -1.12% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $423.64 | +1.32% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $151.28 | -0.61% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $526.73 | -0.18% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $750.51 | -0.23% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $254.07 | -0.51% | 41.4 | 33.44B |